BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Formation Bio Secures $372 Million Series D Funding for AI-Driven Drug Development

by Roman Kasianov   •   June 26, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Startups & Deals   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Formation Bio, an AI-native pharmaceutical company, has raised $372 million in Series D financing, led by a16z and Sanofi. Additional investors include Sequoia, Thrive, Emerson Collective, Lachy Groom, SV Angel Growth, and FPV Ventures. This funding brings new board members Scott Kupor from a16z and Alfred Lin from Sequoia.

#advertisement
AI in Drug Discovery Report 2025

Formation Bio, originally launched as TrialSpark in 2016, utilizes AI to enhance drug development efficiency, addressing high costs and lengthy clinical trials. The company partners with, acquires, or in-licenses drugs to advance them beyond clinical proof of concept.

See also: AI Drug Discovery: Key Trends and Developments in Pharmaceutical Industry

Strategic Focus Areas

Acquisition and In-Licensing: The funds will be used to acquire and in-license clinical-stage assets, benefiting both small biotech firms and large pharmaceutical companies by providing efficient development pathways.

AI Integration: Formation Bio's AI capabilities streamline clinical trial processes and automate tasks such as patient recruitment and adverse event reporting. Their collaboration with OpenAI and Sanofi aims to create advanced AI solutions for drug development.


Because of their tech, data, and operational foundations, Formation Bio has rapidly integrated large language models (LLMs), AI models, and applications throughout its platform. The company's vision is to automate many core drug development functions, such as medical writing, protocol development, biostatistics, report generation, and regulatory intelligence, using fine-tuned and customized LLMs coupled with expert human oversight and reinforcement.

Topics: Startups & Deals   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.